{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:15:24Z","timestamp":1763036124158},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,4,22]],"date-time":"2006-04-22T00:00:00Z","timestamp":1145664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00228-006-0131-1","type":"journal-article","created":{"date-parts":[[2006,4,21]],"date-time":"2006-04-21T12:31:52Z","timestamp":1145622712000},"page":"473-479","source":"Crossref","is-referenced-by-count":65,"title":["Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?"],"prefix":"10.1007","volume":"62","author":[{"given":"David W. J.","family":"Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Strandell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,22]]},"reference":[{"key":"131_CR1","unstructured":"Coulter DM (1996) Does omeprazole cause polymyositis? Proceedings of the Royal Australasian College of Physicians, Annual Clinical and Scientific meeting. Sept. 1996:81 (abstract)"},{"key":"131_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00002018-200225060-00007","volume":"25","author":"DM Coulter","year":"2002","unstructured":"Coulter DM (2002) Signal generation in the New Zealand Intensive Medicines Monitoring Programme. Drug Saf 25:433\u2013439","journal-title":"Drug Saf"},{"key":"131_CR3","unstructured":"Uppsala Monitoring Centre Signal, Omeprazole - polymyositis and rheumatoid arthritis. (July, 1997) Restricted document, contact the UMC for details"},{"key":"131_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre S, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"131_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pds.894","volume":"13","author":"M Stahl","year":"2004","unstructured":"Stahl M, Lindquist M, Edwards IR, Brown EG (2004) Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 13:355\u2013363","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"131_CR6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","volume":"10","author":"IR Edwards","year":"1994","unstructured":"Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Saf 10:93\u2013102","journal-title":"Drug Saf"},{"key":"131_CR7","first-page":"169","volume-title":"Pharmacovigilance","author":"IR Edwards","year":"2002","unstructured":"Edwards IR, Olsson S (2002) WHO programme-global monitoring. In: Mann RD, Andrews EB (eds) Pharmacovigilance. Wiley, London, pp 169\u2013182"},{"key":"131_CR8","unstructured":"Online version of Thompson Micromedex database Physicians\u2019 Desk Reference (Accessed, June 2005)"},{"key":"131_CR9","unstructured":"Online version of Thompson Micromedex database Martindale (Accessed, June 2005)"},{"key":"131_CR10","unstructured":"Online version of Thompson Micromedex database DrugDex (Accessed, June 2005)"},{"issue":"8820","key":"131_CR11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0140-6736(92)92205-T","volume":"340","author":"FJ Garrote","year":"1992","unstructured":"Garrote FJ, Lacambra C, del Ser T, Garcia Diaz B, Obeso G, Folis J (1992) Subacute myopathy during omeprazole therapy. Lancet 340(8820):672","journal-title":"Lancet"},{"key":"131_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1345\/aph.17190","volume":"32","author":"JD Smith","year":"1998","unstructured":"Smith JD, Chang KL, Gums JG (1998) Possible lansoprazole-induced eosinophilic syndrome. Ann Pharmacother 32:196\u2013200","journal-title":"Ann Pharmacother"},{"key":"131_CR13","unstructured":"The Medicines Compendium, Datapharm Communications Ltd. Electronic Medicine Compendium. Electronic version. (Accessed, May 2005). Url: http:\/\/www.medicines.org.uk\/"},{"key":"131_CR14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1345\/aph.1C396","volume":"37","author":"BE Sipe","year":"2003","unstructured":"Sipe BE, Jones RJ, Bokhart GH (2003) Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 37:808\u2013811","journal-title":"Ann Pharmacother"},{"issue":"8708","key":"131_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0140-6736(90)91669-2","volume":"336","author":"IR Edwards","year":"1990","unstructured":"Edwards IR, Lindquist M, Wiholm B-E, Napke E (1990) Quality criteria for early signals of possible adverse drug reactions. Lancet 336(8708):156\u2013158","journal-title":"Lancet"},{"key":"131_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00535-003-1231-7","volume":"39","author":"M Nozaki","year":"2004","unstructured":"Nozaki M, Suzuki T, Hirano M (2004) Rhabdomyolysis associated with omeprazole. J Gastroenterol 39:86","journal-title":"J Gastroenterol"},{"key":"131_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"XQ Li","year":"2004","unstructured":"Li XQ, Anderson TB, Ahlstom M, Weidolf L (2004) Comparison of the inhibitory effect of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821\u2013827","journal-title":"Drug Metab Dispos"},{"key":"131_CR18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2125.2004.02329.x","volume":"59","author":"M Saito","year":"2005","unstructured":"Saito M, Yasui-Furublinkkori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T (2005) Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302\u2013309","journal-title":"Br J Clin Pharmacol"},{"key":"131_CR19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","volume":"49","author":"L Calabresi","year":"2004","unstructured":"Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C (2004) Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in healthy volunteers. Pharmacol Res 49:493\u2013499","journal-title":"Pharmacol Res"},{"issue":"8922","key":"131_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(94)92008-7","volume":"344","author":"K Sivakumar","year":"1994","unstructured":"Sivakumar K, Dalakas MC (1994) Autoimmune syndrome induced by omeprazole. Lancet 344(8922):619\u2013620","journal-title":"Lancet"},{"issue":"8686","key":"131_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0140-6736(90)90260-C","volume":"335","author":"B Burlinson","year":"1990","unstructured":"Burlinson B, Morris SH, Gatehouse DG, Tweats DJ (1990) Genotoxicity studies of gastric acid inhibiting drugs. Lancet 335(8686):419","journal-title":"Lancet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0131-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0131-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:29Z","timestamp":1558702289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0131-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,22]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0131-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,22]]}}}